Inter-Residue Geometry Attention for Antibody-Specific Epitope Prediction

Antibodies neutralize foreign antigens by binding to specific surface regions called epitopes. Computational epitope prediction is critical for understanding immune recognition and guiding antibody engineering. However, existing methods face three fundamental challenges: antibody-aware models encode each chain independently and combine them only at a late stage, failing to capture co-dependent structural features that define binding interfaces, whereas severe class imbalance and scarcity of known antibody-antigen complexes render standard training objectives ineffective. We propose EpiFormer, a general encoder-decoder framework that addresses these challenges jointly. Our key design principle is interleaved cross-attention within GNN encoding layers, enabling bidirectional antigen-antibody information flow throughout representation learning rather than only at the output. This early-fusion principle is backbone-agnostic, providing consistent gains across GNN architectures from simple GCNs to equivariant models. We further show that sparsity-aware objectives are effective when paired with early-fusion architectures for the epitope prediction task. EpiFormer improves over the previous best method by over 40% in F1 score on standard benchmarks, demonstrating generalizability and cross-dataset transferability. Notably, EpiFormer discovers known biological principles as emergent behaviors of end-to-end training, where the learned cross-attention gates favor antigen-to-antibody information flow, consistent with the asymmetric roles of the two chains at the binding interface, and the model's preference for geometric over evolutionary features aligns with the established finding that epitope residues are not evolutionarily conserved. The source code is available at: https://github.com/mansoor181/epiformer.git

DuaDeep-SeqAffinity is a sequence-only deep learning framework that predicts antibody--antigen binding affinity directly from primary amino acid sequences, avoiding the cost and scarcity of resolved three-dimensional structures. The antigen and the antibody heavy and light chains are processed as three independent streams, each embedded with a frozen ESM-2 protein language model and passed through parallel Transformer and convolutional neural network (CNN) branches before late fusion, a decoupled design intended to preserve local complementarity-determining region (CDR) signal that monolithic encoders can dilute. On a sequence-disjoint split of the AbRank benchmark, the model achieves a Pearson correlation of 0.683, an R^2 of 0.460, and a pairwise ranking AUC of 0.895, significantly outperforming single-branch ablations (paired t-test, p < 0.05). Attention-map and gradient-based saliency analyses further show that the model preferentially attends to CDR loops and candidate epitope residues, supporting its use as a scalable, structure-free tool for high-throughput antibody screening.

Epitopes determine where antibodies bind antigens and shape downstream therapeutic properties such as functional blockade and escape resistance, making epitope understanding central to antibody drug discovery. Although large language models (LLMs) have shown strong biomedical reasoning ability, it remains unclear whether they can infer epitope information directly from antigen and antibody sequences. Existing epitope resources typically focus on isolated prediction tasks or rely on specialized structural settings, while general protein benchmarks do not evaluate epitope-centered decisions across the antibody development workflow. To address this gap, we introduce EpiBench, a closed-book, sequence-based, and automatically scorable benchmark for evaluating epitope reasoning in LLMs. EpiBench contains 1,609 curated samples grounded in structural antibody--antigen contacts, curated functional B-cell assays, and deep mutational scanning escape measurements. It covers five connected tasks: targetable region discovery, antibody-conditioned epitope identification, epitope binning, functional epitope assessment, and antibody escape assessment, with controlled sampling to reduce shortcut-based evaluation artifacts. We evaluate nine general-purpose LLMs and analyze their behavior through task-specific baselines, antigen length stratification, explicit-reasoning comparison, and failure-mode inspection. The results show that current LLMs capture partial epitope-related signals but remain limited in antibody-specific sequence grounding, long-context residue localization, and biologically grounded reasoning. Therefore, EpiBench provides a diagnostic testbed for measuring and improving sequence-aware biomedical LLMs toward reliable LLM-assisted antibody discovery.